News
ABCM
23.99
0.00%
0.00
Weekly Report: what happened at ABCM last week (0226-0301)?
Weekly Report · 03/04 09:19
Weekly Report: what happened at ABCM last week (0219-0223)?
Weekly Report · 02/26 09:20
Weekly Report: what happened at ABCM last week (0212-0216)?
Weekly Report · 02/19 09:21
Weekly Report: what happened at ABCM last week (0205-0209)?
Weekly Report · 02/12 09:19
Weekly Report: what happened at ABCM last week (0129-0202)?
Weekly Report · 02/05 09:21
Danaher forecasts revenue decline in 2024, shares fall
Danaher forecasts revenue decline in 2024, shares fall 4% before the bell. Life sciences firm beat expectations for fourth-quarter profit and sales driven by strength in respiratory testing segment. Rising interest rates have squeezed funding for drug development programs. Danaher's $5.7 billion acquisition of Abcam expected to cushion the hit.
Reuters · 01/30 12:05
Weekly Report: what happened at ABCM last week (0122-0126)?
Weekly Report · 01/29 09:19
Weekly Report: what happened at ABCM last week (0115-0119)?
Weekly Report · 01/22 09:20
Weekly Report: what happened at ABCM last week (0108-0112)?
Weekly Report · 01/15 09:19
Weekly Report: what happened at ABCM last week (0101-0105)?
Weekly Report · 01/08 09:20
Weekly Report: what happened at ABCM last week (1225-1229)?
Weekly Report · 01/01 09:19
Weekly Report: what happened at ABCM last week (1218-1222)?
Weekly Report · 12/25/2023 09:21
Weekly Report: what happened at ABCM last week (1211-1215)?
Weekly Report · 12/18/2023 09:22
Weekly Report: what happened at ABCM last week (1204-1208)?
Weekly Report · 12/11/2023 09:21
*News On Abcam PLC (ABCM) Now Under DHR
Dow Jones · 12/06/2023 22:08
Abcam Plc: Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
Press release · 12/06/2023 15:06
UPDATE 1-Danaher completes $5.7 billion acquisition of Abcam
Medical tools supplier danaher completes $5.7 billion acquisition of abcam. Danaher agreed to buy protein consumables maker in september for $24 per share. Abcam founder jonathan milner opposed the deal saying the offer undervalued the company. Milner later suspended his campaign against the acquisition.
Reuters · 12/06/2023 13:09
Danaher completes $5.7 bln acquisition of Abcam
Danaher completes $5.7 billion acquisition of abcam abczf.pk. Medical tools supplier says the deal faced opposition from the founder of the company. Abcam is a maker of medical tools for the military and the military industrial sectors.
Reuters · 12/06/2023 12:41
Press Release: Danaher Completes Acquisition of Abcam
Danaher completes its acquisition of abcam plc for $24.00 per share in cash. Trading of abcam adss on nasdaq has been suspended. Abcam has become an indirect wholly owned subsidiary of danaher. Danaher is a leading global life sciences and diagnostics innovator.
Dow Jones · 12/06/2023 12:30
*Danaher Completes Acquisition Of Abcam >DHR ABCM
Dow Jones · 12/06/2023 12:30
More
Webull provides a variety of real-time ABCM stock news. You can receive the latest news about Abcam Plc through multiple platforms. This information may help you make smarter investment decisions.
About ABCM
Abcam plc is a global life science company. The Company serves customers at the forefront of life science research through the identification, development, and distribution of biological reagents. Its products are used by researchers around the world to study biological pathways critical for scientific research, diagnostics, and drug discovery. It offers a selection of products in its catalogue to support research on proteins in biological pathways. Its principal catalogue product lines include primary and secondary antibodies, conjugated antibodies and conjugation kits, and singleplex immunoassays. It offers a range of peptides and proteins, which include cytokines, growth factors, and enzymes. It offers a range of knockout cell lines and lysates, which are used for its in-house validation needs and are also made available to its customers for their own research. It offers a variety of other products, including cellular activity kits, biochemicals and cell signaling pathway tools.